DDInter1744 DDInter1008
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) DHCR7
DHCR7 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Ketoconazole
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Posaconazole
Posaconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) regulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) upregulates {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is regulated by {v} (Gene) FDFT1
FDFT1 {u} (Gene) is upregulated by {v} (Compound) Ketoconazole
Tamoxifen {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Itraconazole
Itraconazole {u} (Compound) resembles {v} (Compound) Ketoconazole
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Ketoconazole (Compound)
Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketoconazole (Compound)
Tamoxifen (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) is upregulated by Ketoconazole (Compound)
Tamoxifen (Compound) binds DHCR7 (Gene) and Tamoxifen (Compound) upregulates DHCR7 (Gene) and DHCR7 (Gene) is upregulated by Ketoconazole (Compound)
Tamoxifen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Ketoconazole (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole and Posaconazole (Compound) resembles Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)
Tamoxifen (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) regulates SLC2A6 (Gene) and SLC2A6 (Gene) is upregulated by Ketoconazole (Compound)
Tamoxifen (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is regulated by FDFT1 (Gene) and FDFT1 (Gene) is upregulated by Ketoconazole (Compound)
Tamoxifen (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Itraconazole (Compound) and Itraconazole (Compound) resembles Ketoconazole (Compound)